PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Polymyxin B Haemoadsorption Reduces Mortality in Endotoxic Septic Shock

TIGRIS trial indicates improved outcomes for patients with specific endotoxin activity in septic shock.
Polymyxin Bantibioticsseptic shockphase 3 trialBayesian analysis IDSA
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Neyra JA, Legrand M, Tidswell MA, Al-Khafaji A, Galphin C, Rains R, Davison D, Tolwani A, Chen JT, Bender WS, Busse LW, Meena NK, DellaVolpe J, Williams GW, Kashani KB, Gunnerson KJ, McMahon BA, Eaton J, Khan S, Kohli-Seth R, Jagpal S, Klein D, Kamaluddin E, Foster DM, Walker PM, Tomlinson G, Kellum JA

Citation: Neyra JA, Legrand M, Tidswell MA, et al. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial. The Lancet. Respiratory medicine. 2026;14(5):443-452. doi:10.1016/S2213-2600(26)00047-0

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →